The Apheris product is used by some of the largest global life sciences organizations to collaborate on sensitive, proprietary data across teams, borders, and organizations.
Our customers unlock the value of complementary data and collaboratively train machine learning models on their distributed datasets to improve accuracy and generalizability to meet the precision required for industrial settings.
Meet our Founders
Robin Röhm
Co-Founder & CEO
Robin studied medicine, philosophy and mathematics and was trained in global banking at UBS. In one of his previous start-ups, he lost multiple customers as data couldn’t be centralized due to regulatory constraints. He is driving the vision, strategy, and culture of Apheris.
Michael Höh
Co-Founder & CTO
Michael has a PhD in physics and computer science. He was trained at BCG where he built digital solutions and AI applications for industrial clients. As CTO he leads our platform architecture and design, our engineering target picture, technical customer commitments and legal and contractual scoping.
Events we're joining
Our CEO, Robin Röhm, is invited to speak at NVIDIA’s GTC. He'll be speaking on Federated Data Collaboration in BioPharma – Leveraging NVIDIA FLARE and BioNeMo.
Chris Woodward, Product Manager, and Jan Stücke, Product Marketing, are joining the ML Commons events. Meet them there
Chris Woodward, Product Manager, and Jan Stücke, Product Marketing, are joining the Flower Summit in London. Meet them there
Apheris joined GA4GH as an organizational member, and our CEO, Robin Röhm,will represent our concept of Computational Governance with this international community dedicated to making genomic and health data usable, secure, and ethically governed.
* John Karanicolas, Head of Computational Drug Discovery, AbbVie * Mohammed AlQuraishi, Assistant Professor, Systems Biology, Columbia University * Robin Röhm, CEO and co-founder of Apheris How life sciences organizations can collaboratively train AI models across proprietary datasets—without moving data or compromising IP.
Our VP of Product, Ellie Dobson, will speak about safely connecting life sciences data for collaborative AI.
Our CEO, Robin Röhm, will participate in a panel discussion with 1. Justin Scheer, VP of In-Silico Drug Discovery, J&J 2. John K, AbbVie Head of Computation Chemistry, AbbVie 3. Dr. Mohammed Al Quraishi, Assistent Professor, Columbia University
ROCHE / APHERIS talk about INTONATE. Making distributed, proprietary Multiple-Sklerosis data securely accessible via federated computing and computational governance.
Lukas is flying to London to attend the DIGI-TECH Pharma & AI event. He's more than happy to connect over coffee and talk about the AI in Structural Biology (AISB) network - an industry initiative aiming to improve AI models for industrial drug discovery by training models on proprietary pharma data.
We are very grateful for the invitation to the Bioinformatics Industry Forum - thank you Elixir! Lukas from the Apheris team will be attending this event to talk about federated data networks in life sciences. Contact us if you'll be attending
Robin has been invited to speak about the AI Structural Biology (AISB) Network. Thank you for the invitation - we look forward to speaking with industry leaders about the latest breakthroughs in industrial AI research for drug discovery.
Nic from the Apheris team is traveling to beautiful Paris to meet with our friends at NVIDIA. We are looking forward to this event and to speaking with tech enthusiasts about federated learning and more.
Our culture is based upon our core values
Impact
We are driven by impact and strive for the impossible
Collaboration
Through collaboration, we create a whole that is far greater than the sum of its parts
Responsibility
We are responsible together and commit to ownership
Humility
We have the humility and hunger to learn
